To conduct a double-blined randomized, placebo-controlled pilot study to evaluate the safety
and efficacy of statin therapy (atorvastatin 40 mg daily) for the treatment of NASH and
hepatic fibrosis.
The findings from this study will facilitate the design of a larger interventional study with
proper consideration of biological disparities and eventually inform NASH treatment and
personalized HCC chemoprevention approach using statins.